WebbCalc
WebbCalc — Peds Abx Calculator
kg
All
Ear / Nose / Throat
Dental / Oral
Respiratory
Eye / Periorbital
Skin / Soft Tissue
Urinary / Genital
Sexual Health / Exposures
Abdominal / GI
Bone / Joint / Trauma
CNS
Systemic / Bloodstream
Tick-borne
Erythromycin 0.5% ophthalmic ointment
· Eye/Ear
Approximately 1-cm ribbon QID
Polymyxin B-trimethoprim ophthalmic solution
· Eye/Ear
1 drop q3h
Ofloxacin 0.3% ophthalmic solution
· Eye/Ear
Days 1–2: 1–2 drops q2–4h; days 3–7: 1–2 drops QID
Ciprofloxacin 0.3% ophthalmic solution
· Eye/Ear
1–2 drops q2h while awake for 2 days, then q4h while awake for 5 days
Moxifloxacin 0.5% ophthalmic solution (Vigamox regimen)
· Eye/Ear
1 drop TID
Tobramycin 0.3% ophthalmic solution
· Eye/Ear
1–2 drops q4h for mild/moderate infection
Ofloxacin 0.3% otic — otitis externa
· Eye/Ear
Age 6 months–<13 years: 5 drops daily; ≥13 years: 10 drops daily
Ofloxacin 0.3% otic — AOM with tympanostomy tubes
· Eye/Ear
5 drops BID
Ofloxacin 0.3% otic — chronic suppurative OM with perforation
· Eye/Ear
10 drops BID
Ciprofloxacin 0.3% / dexamethasone 0.1% (Ciprodex) — OE / tube otorrhea
· Eye/Ear
4 drops BID
Neomycin / polymyxin B / hydrocortisone otic — OE
· Eye/Ear
3 drops 3–4 times daily
Ciprofloxacin / hydrocortisone (Cipro HC) otic — OE
· Eye/Ear
3 drops BID
Mupirocin 2% ointment
· Topical
Localized impetigo: apply 2–3 times daily
Bacitracin topical
· Topical
Selected minor superficial wounds: apply 1–3 times daily
Ozenoxacin 1% cream
· Topical
Impetigo: apply BID
Clotrimazole 1% cream
· Topical
Tinea corporis/cruris/pedis or cutaneous Candida: apply BID
Miconazole 2% cream
· Topical
Tinea / cutaneous Candida: apply BID
Terbinafine 1% cream
· Topical
Dermatophyte skin infection: apply once or twice daily per product/site
Nystatin 100,000 units/g cream
· Topical
Cutaneous Candida / candidal diaper dermatitis: apply BID
Ketoconazole 2% cream
· Topical
Selected tinea / cutaneous Candida: apply daily
Ketoconazole 2% shampoo
· Topical
Adjunct to systemic therapy for tinea capitis
Selenium sulfide 1–2.5% shampoo
· Topical
Adjunct to systemic therapy for tinea capitis
Permethrin 5% cream — scabies
· Topical/Parasite
Apply over recommended body surface; wash off after 8–14 hours
Ivermectin PO — selected scabies
· Topical/Parasite
200 micrograms/kg per dose
Permethrin 1% lotion — head lice
· Topical/Parasite
Apply per product, rinse after 10 minutes
Spinosad 0.9% topical suspension — head lice
· Topical/Parasite
Apply to dry scalp/hair; rinse after 10 minutes
Pyrantel pamoate PO — pinworm
· Topical/Parasite
11 mg/kg pyrantel base once
Albendazole PO — pinworm
· Topical/Parasite
400 mg once
Nitazoxanide PO — Giardia / selected Cryptosporidium diarrhea
· Topical/Parasite
Age 1–3 years: 100 mg BID; 4–11 years: 200 mg BID; ≥12 years: 500 mg BID
Tinidazole PO — Giardia
· Topical/Parasite
Age >3 years: 50 mg/kg once
Clotrimazole 1% cream — balanitis (Candida)
· Topical
Thin layer BID
Miconazole 2% cream — balanitis (Candida alternative)
· Topical
Thin layer BID
Irritant balanitis — no antimicrobial
· Topical
Gentle cleansing, avoid irritants, barrier care
Amoxicillin PO — AOM / uncomplicated bacterial CAP
· Oral
45 mg/kg BID
Amoxicillin PO — GAS pharyngitis
· Oral
50 mg/kg once daily OR 25 mg/kg BID
Amoxicillin PO — dental infection
· Oral
22.5 mg/kg BID
Amoxicillin-clavulanate PO — bites / dental infection
· Oral
22.5 mg/kg BID
Amoxicillin-clavulanate PO — high-dose AOM / sinus-flora preseptal infection
· Oral
45 mg/kg BID
Amoxicillin-clavulanate PO — selected high-dose bacterial sinusitis
· Oral
45 mg/kg BID
Penicillin V PO — GAS pharyngitis
· Oral
Children: 250 mg BID or TID; adolescents: 500 mg BID
Cephalexin PO — uncomplicated cellulitis
· Oral
25 mg/kg TID
Cephalexin PO — uncomplicated UTI (cystitis)
· Oral
25 mg/kg BID
Cephalexin PO — GAS pharyngitis
· Oral
20 mg/kg BID
Cefadroxil PO — GAS pharyngitis
· Oral
30 mg/kg once daily
Cefdinir PO — selected AOM / respiratory alternative
· Oral
7 mg/kg BID
Cefuroxime axetil PO — selected AOM / sinusitis alternative
· Oral
15 mg/kg BID
Cefpodoxime PO — AOM / sinusitis
· Oral
5 mg/kg q12h
Clindamycin PO — susceptible skin / dental infection
· Oral
10 mg/kg q8h
Clindamycin PO — GAS pharyngitis
· Oral
7 mg/kg TID
TMP-SMX PO — susceptible MRSA skin infection / UTI
· Oral
5 mg TMP/kg BID
Azithromycin PO — atypical CAP
· Oral
Day 1: 10 mg/kg; days 2–5: 5 mg/kg once daily
Azithromycin PO — pertussis, age ≥6 months
· Oral
Day 1: 10 mg/kg; days 2–5: 5 mg/kg once daily
Azithromycin PO — pertussis, age <6 months
· Oral
10 mg/kg once daily
Azithromycin PO — GAS pharyngitis alternative
· Oral
Day 1: 12 mg/kg; days 2–5: 6 mg/kg once daily
Clarithromycin PO — GAS pharyngitis alternative
· Oral
7.5 mg/kg BID
Nitrofurantoin suspension PO — cystitis
· Oral
5–7 mg/kg DAILY, divided QID
Nitrofurantoin monohydrate/macrocrystals (Macrobid) PO — adolescent cystitis
· Oral
100 mg BID
Ciprofloxacin PO — selected complicated UTI / susceptible gram-negative infection
· Oral
15 mg/kg q12h
Metronidazole PO — anaerobic infection
· Oral
10 mg/kg q8h
Vancomycin PO — nonfulminant C. difficile infection
· Oral
10 mg/kg QID
Doxycycline PO — early localized Lyme disease
· Oral
2.2 mg/kg BID
Doxycycline PO — qualifying Lyme prophylaxis
· Oral
4.4 mg/kg once
Amoxicillin PO — early localized Lyme disease
· Oral
50 mg/kg DAILY, divided TID
Cefuroxime axetil PO — early localized Lyme disease
· Oral
15 mg/kg BID
Uncomplicated gonorrhea — ceftriaxone
· Adolescent
<150 kg: 500 mg IM once; ≥150 kg: 1,000 mg IM once
Urethritis / cervicitis / possible STI exposure — ceftriaxone + doxycycline
· Adolescent
FIXED: Ceftriaxone 500 mg IM once (1 g if ≥150 kg) + doxycycline 100 mg PO BID
Chlamydia — doxycycline
· Adolescent
100 mg PO BID
Outpatient PID — ceftriaxone + doxycycline + metronidazole
· Adolescent
Ceftriaxone 500 mg IM once; doxycycline 100 mg PO BID; metronidazole 500 mg PO BID
Outpatient PID alternative — cefoxitin + probenecid + doxycycline + metronidazole
· Adolescent
Cefoxitin 2 g IM once AND probenecid 1 g PO once; doxycycline 100 mg BID; metronidazole 500 mg BID
Bacterial vaginosis — metronidazole
· Adolescent
500 mg PO BID
Trichomoniasis — metronidazole
· Adolescent
Females: 500 mg PO BID for 7 days; males: 2,000 mg PO once
Uncomplicated vulvovaginal candidiasis — fluconazole
· Adolescent
150 mg PO once
Vulvovaginal candidiasis — clotrimazole vaginal cream
· Adolescent
1%: 5 g intravaginally daily for 7–14 days; OR 2%: 5 g daily for 3 days
Vulvovaginal candidiasis — miconazole vaginal cream
· Adolescent
2%: 5 g intravaginally daily for 7 days; OR 4%: 5 g daily for 3 days
First episode genital HSV — valacyclovir
· Adolescent
1,000 mg PO BID
Recurrent genital HSV — valacyclovir
· Adolescent
500 mg PO BID for 3 days OR 1,000 mg PO daily for 5 days
Nystatin oral suspension 100,000 units/mL — thrush
· Oral
Infants: 2 mL QID; older children: 4–6 mL QID
Fluconazole PO — oropharyngeal candidiasis, age ≥6 months
· Oral
Day 1: 6 mg/kg; then 3 mg/kg daily
Griseofulvin microsize PO — tinea capitis
· Oral
20–25 mg/kg DAILY, once daily or divided
Terbinafine PO — selected tinea capitis
· Oral
4–6 mg/kg once daily
Oseltamivir PO — influenza treatment, age ≥1 year
· Antiviral
Weight-tiered BID dosing (6 mg/mL suspension)
Oseltamivir PO — influenza treatment, term infant <1 year
· Antiviral
CDC: 3 mg/kg BID; AAP alternative for 9–11 months: 3.5 mg/kg BID
Acyclovir PO — selected severe early HSV gingivostomatitis
· Antiviral
10 mg/kg 5 times daily
Valacyclovir PO — herpes labialis
· Antiviral
Age ≥12 years: 2,000 mg q12h for 2 doses
Valacyclovir PO — selected varicella treatment
· Antiviral
Age 2–<18 years: 20 mg/kg TID
Cephalexin PO — pyelonephritis (standard)
· Oral
25 mg/kg TID
Cephalexin PO — pyelonephritis (high-dose institutional)
· Oral
50 mg/kg TID
Cefixime PO — pyelonephritis, age ≥6 months
· Oral
8 mg/kg once daily, or 4 mg/kg BID
TMP-SMX PO — pyelonephritis (susceptibility-directed)
· Oral
5 mg TMP/kg BID
Amoxicillin-clavulanate PO — pyelonephritis (susceptibility-directed)
· Oral
25 mg amoxicillin/kg BID
Ciprofloxacin PO — pyelonephritis (resistant organism/allergy)
· Oral
15 mg/kg BID
Levofloxacin PO — epididymitis, enteric only (GC ruled out)
· Adolescent
FIXED: 500 mg PO daily
Prepubertal epididymitis — supportive / culture-directed
· Oral
No antibiotic without evidence of bacterial infection; bacterial UTI-associated: use a pediatric UTI/pyelo regimen
Cephalexin PO — prepubertal epididymitis with evidence of UTI
· Oral
25 mg/kg BID
Doxycycline PO — PCN-allergic nonpregnant adolescent, early syphilis
· Adolescent
FIXED: 100 mg BID
Doxycycline PO — PCN-allergic nonpregnant adolescent, late latent/unknown
· Adolescent
FIXED: 100 mg BID
nPEP Option A — Biktarvy alone (age ≥2 y, ≥14 kg)
· Oral
FIXED by weight band: 14–<25 kg: 30/120/15 mg once daily; ≥25 kg: 50/200/25 mg once daily
nPEP Option B — dolutegravir + Truvada (age ≥2 y, ≥17 kg)
· Oral
FIXED by weight band. Truvada (FTC/TDF): 17–<22 kg 100/150 mg; 22–<28 kg 133/200 mg; 28–<35 kg 167/250 mg; ≥35 kg 200/300 mg daily. PLUS dolutegravir: ≥20 kg 50 mg film-coated daily; 14–<20 kg Tivicay PD 25 mg daily
nPEP Option C — dolutegravir + Descovy (age ≥2 y, ≥14 kg)
· Oral
FIXED by weight band. Descovy (FTC/TAF): 14–<25 kg 120/15 mg; ≥25 kg 200/25 mg daily. PLUS dolutegravir per Option B weight band
nPEP younger child — dolutegravir + zidovudine + emtricitabine
· Oral
Tivicay PD (age ≥4 wk): 3–<6 kg 5 mg; 6–<10 kg 15 mg; 10–<14 kg 20 mg; 14–<20 kg 25 mg daily. Zidovudine (≥4 wk, PMA ≥35 wk): 4–<9 kg 12 mg/kg BID; 9–<30 kg 9 mg/kg BID. Emtricitabine solution: <3 mo 3 mg/kg daily; ≥3 mo 6 mg/kg daily
Metronidazole PO — bacterial vaginosis
· Adolescent
FIXED: 500 mg PO BID
Metronidazole 0.75% gel — bacterial vaginosis
· Adolescent
FIXED: 5 g intravaginally once daily
Clindamycin 2% cream — bacterial vaginosis
· Adolescent
FIXED: 5 g intravaginally nightly
Clindamycin PO — bacterial vaginosis (alternative)
· Adolescent
FIXED: 300 mg PO BID
Amoxicillin-clavulanate PO — PTA outpatient / step-down
· Oral
45 mg amoxicillin/kg BID
Clindamycin PO — PTA/RPA allergy / step-down
· Oral
10 mg/kg TID
Cephalexin PO — osteomyelitis/septic arthritis MSSA step-down
· Oral
50 mg/kg TID
Clindamycin PO — osteomyelitis/septic arthritis step-down
· Oral
13 mg/kg q8h
Cephalexin PO — bacterial balanitis with cellulitis
· Oral
20 mg/kg TID
Atovaquone + azithromycin PO — babesiosis, outpatient
· Oral
Atovaquone 20 mg/kg q12h + azithromycin 10 mg/kg once on day 1, then 5 mg/kg q24h
Clindamycin + quinine sulfate PO — babesiosis alternative
· Oral
Clindamycin 7–10 mg/kg q8h + quinine sulfate 8 mg/kg (of sulfate SALT) q8h
Azithromycin PO — AOM, severe PCN/cephalosporin allergy
· Oral
10 mg/kg day 1, then 5 mg/kg q24h days 2–5
Clindamycin PO — AOM, PCN allergy
· Oral
10 mg/kg TID
Clindamycin PO — preseptal cellulitis, PCN allergy
· Oral
10 mg/kg TID
Levofloxacin PO — preseptal cellulitis/sinusitis, severe beta-lactam allergy
· Oral
<5 y: 10 mg/kg q12h; ≥5 y: 10 mg/kg q24h
TMP-SMX + clindamycin PO — bite, PCN allergy
· Oral
TMP-SMX 5 mg TMP/kg BID + clindamycin 10 mg/kg TID
Clindamycin PO — bacterial balanitis with cellulitis, PCN allergy
· Oral
10 mg/kg TID
Levofloxacin PO or IV — selected respiratory infection / alternative therapy
· Oral
Age 6 months to <5 years: 10 mg/kg q12h; age ≥5 years: 10 mg/kg q24h
Doxycycline PO or IV — suspected rickettsial disease
· Oral
2.2 mg/kg q12h
Clindamycin IV or PO — bone-joint infection
· IV/IM
13 mg/kg q8h
Linezolid PO or IV — selected resistant gram-positive infection
· IV/IM
<12 years: 10 mg/kg q8h; ≥12 years: 600 mg q12h
Doxycycline PO or IV — ehrlichiosis
· Oral
2.2 mg/kg q12h (larger adolescents 100 mg q12h)
Doxycycline PO or IV — anaplasmosis
· Oral
2.2 mg/kg q12h (larger adolescents 100 mg q12h)
Ampicillin IV — susceptible non-CNS infection
· IV/IM
50 mg/kg q6h
Ampicillin-sulbactam IV — bite, dental, deep-neck, orbital infection
· IV/IM
50 mg ampicillin/kg q6h
Cefazolin IV — uncomplicated cellulitis / MSSA infection
· IV/IM
25 mg/kg q8h
Cefazolin IV — severe MSSA / bone-joint infection
· IV/IM
50 mg/kg q8h
Ceftriaxone IV or IM — non-CNS infection
· IV/IM
50 mg/kg q24h
Ceftriaxone IM or IV — AOM when indicated
· IV/IM
50 mg/kg q24h
Ceftriaxone IV — meningitis
· IV/IM
50 mg/kg q12h
Clindamycin IV — susceptible skin / anaerobic infection
· IV/IM
10 mg/kg q8h
Metronidazole IV — anaerobic infection
· IV/IM
10 mg/kg q8h
Benzathine penicillin G (Bicillin L-A) IM — GAS pharyngitis
· IV/IM
<27 kg: 600,000 units once; ≥27 kg: 1,200,000 units once
Ciprofloxacin IV — selected susceptible gram-negative infection
· IV/IM
10 mg/kg q8h
Aqueous penicillin G IV — susceptible non-CNS infection
· IV/IM
200,000 units/kg DAILY, divided q4h
Aqueous penicillin G IV — selected severe infection / meningitis
· IV/IM
400,000 units/kg DAILY, divided q4h
Cefepime IV — febrile neutropenia / serious gram-negative infection
· IV/IM
50 mg/kg q8h
Ceftazidime IV — selected Pseudomonas / gram-negative infection
· IV/IM
50 mg/kg q8h
Piperacillin-tazobactam IV — severe polymicrobial infection
· IV/IM
100 mg piperacillin/kg q6h
Meropenem IV — serious susceptible infection, non-CNS
· IV/IM
20 mg/kg q8h
Meropenem IV — meningitis
· IV/IM
40 mg/kg q8h
Ertapenem IV or IM — selected ESBL / intra-abdominal infection
· IV/IM
Age 3 months–12 years: 15 mg/kg q12h; ≥13 years: 1,000 mg q24h
Nafcillin or oxacillin IV — serious MSSA infection
· IV/IM
50 mg/kg q6h
Aztreonam IV — selected gram-negative coverage in allergy pathway
· IV/IM
30 mg/kg q6–8h
Gentamicin IV — selected serious gram-negative infection
· IV/IM
Extended-interval protocols commonly 5–7 mg/kg q24h
Tobramycin IV — selected serious gram-negative infection
· IV/IM
Extended-interval protocols commonly 5–7 mg/kg q24h
Vancomycin IV — serious suspected MRSA / meningitis combination
· IV/IM
Common pediatric starting range 15–20 mg/kg q6–8h
Cefoxitin IV — selected intra-abdominal / pelvic infection, age ≥3 months
· IV/IM
80–160 mg/kg DAILY, divided into 4–6 doses
Cefoxitin IV — adolescent PID inpatient alternative
· IV/IM
2,000 mg q6h PLUS doxycycline 100 mg PO/IV q12h
Cefotetan IV — adolescent PID inpatient alternative
· IV/IM
2,000 mg q12h PLUS doxycycline 100 mg PO/IV q12h
Acyclovir IV — suspected HSV encephalitis, age 3 months–<12 years
· Antiviral
One institutional regimen: 15 mg/kg q8h
Acyclovir IV — suspected HSV encephalitis, age ≥12 years
· Antiviral
10 mg/kg q8h
Early-onset sepsis (0–7 days), term — ampicillin IV + gentamicin IV
· Neonatal
Ampicillin 50 mg/kg IV q8h (or 100 mg/kg/day ÷ q12h) + gentamicin 4–5 mg/kg IV q24h (extended-interval)
Early-onset sepsis, preterm <35 weeks — ampicillin IV + gentamicin IV
· Neonatal
Ampicillin 50 mg/kg IV q12h + gentamicin 3–4 mg/kg IV q24–48h
Late-onset sepsis (>7 days) — ampicillin IV + gentamicin IV
· Neonatal
Ampicillin 33.3–66.7 mg/kg IV q8h OR 25–50 mg/kg IV q6h (100–200 mg/kg/day) + gentamicin 4–5 mg/kg IV q24–36h
Meningitis (all neonatal ages) — ampicillin IV + gentamicin IV
· Neonatal
Ampicillin 50–100 mg/kg IV q8h OR 37.5–75 mg/kg IV q6h (150–300 mg/kg/day) + gentamicin 2.5 mg/kg IV q8h OR 5 mg/kg IV q24h
Intrapartum chorioamnionitis (MATERNAL) — ampicillin IV + gentamicin IV
· Neonatal
FIXED: ampicillin 2 g IV q6h + gentamicin 5 mg/kg IV q24h OR 1.5 mg/kg IV q8h (maternal weight)
Acyclovir, suspected HSV
· Neonatal
20 mg/kg q8h
Ceftazidime, including meningitis
· Neonatal
50 mg/kg q12h
Ceftazidime
· Neonatal
50 mg/kg q8h
Age 29–60 days, non-CNS empiric therapy — ceftriaxone IV
· Neonatal
50 mg/kg q24h
Age 29–60 days, suspected meningitis — ceftriaxone IV
· Neonatal
50 mg/kg q12h
Age 29–60 days, suspected HSV CNS infection — acyclovir IV
· Neonatal
20 mg/kg q8h
Young infant / neonate, resistant gram-positive coverage — vancomycin IV
· Neonatal
Local age/PMA/renal/AUC protocol required
Age 61–89 days and still <3 calendar months, suspected HSV encephalitis — acyclovir IV
· Neonatal
20 mg/kg q8h
Neonatal congenital syphilis — aqueous crystalline penicillin G IV
· Neonatal
50,000 units/kg q12h during first 7 days; q8h thereafter
Ceftriaxone + metronidazole IV — appendicitis (incl. many perforated)
· IV/IM
Ceftriaxone 50 mg/kg q24h + metronidazole 30 mg/kg q24h
Piperacillin-tazobactam IV — selected complicated appendicitis
· IV/IM
80 mg piperacillin/kg q6h
Ciprofloxacin + metronidazole IV — appendicitis, beta-lactam allergy
· IV/IM
Ciprofloxacin 15 mg/kg q12h + metronidazole 30 mg/kg q24h
Ceftriaxone IV/IM — pyelonephritis
· IV/IM
50 mg/kg q24h
Ciprofloxacin IV — pyelonephritis (parenteral alternative)
· IV/IM
10 mg/kg q8h
Ceftriaxone IM + doxycycline PO — epididymitis, likely GC/CT
· Adolescent
FIXED: Ceftriaxone 500 mg IM once (1 g if ≥150 kg) + doxycycline 100 mg PO BID
Ceftriaxone IM + levofloxacin PO — epididymitis, STI + enteric risk
· Adolescent
FIXED: Ceftriaxone 500 mg IM once (1 g if ≥150 kg) + levofloxacin 500 mg PO daily
Benzathine penicillin G (Bicillin L-A) IM — child, primary/secondary/early latent
· IV/IM
50,000 units/kg IM once
Benzathine penicillin G IM — child, late latent/unknown duration
· IV/IM
50,000 units/kg IM weekly × 3 doses
Benzathine penicillin G IM — adolescent/adult early syphilis
· Adolescent
FIXED: 2.4 million units IM once
Benzathine penicillin G IM — adolescent/adult late latent/unknown
· Adolescent
FIXED: 2.4 million units IM weekly × 3
Aqueous crystalline penicillin G IV — pediatric neurosyphilis/ocular/otic
· IV/IM
50,000 units/kg q4–6h (200,000–300,000 units/kg/day)
Ampicillin-sulbactam IV — PTA/RPA initial
· IV/IM
50 mg ampicillin/kg q6h
Clindamycin IV — PTA/RPA allergy alternative
· IV/IM
10 mg/kg q8h
Cefazolin IV — open fracture type I–II
· IV/IM
30 mg/kg q8h
Clindamycin IV — open fracture, beta-lactam allergy
· IV/IM
10 mg/kg q8h
Ceftriaxone + vancomycin IV — open fracture type III (one protocol)
· IV/IM
Ceftriaxone 50 mg/kg q12h + vancomycin per local protocol (see vanc starting protocol)
Aqueous penicillin G IV — open fracture farm/soil/fecal add-on
· IV/IM
100,000 units/kg q6h
Cefazolin IV — osteomyelitis/septic arthritis (MSSA)
· IV/IM
50 mg/kg q8h
Nafcillin or oxacillin IV — osteomyelitis/septic arthritis (MSSA)
· IV/IM
50 mg/kg q6h
Clindamycin IV — osteomyelitis/septic arthritis (MRSA/allergy)
· IV/IM
13 mg/kg q8h
Vancomycin IV — osteomyelitis/septic arthritis (severe/MRSA)
· IV/IM
See vancomycin starting protocol; often initially with cefazolin
Vancomycin IV starting protocol — age 3 months to <12 years
· IV/IM
17.5 mg/kg IV q6h
Vancomycin IV starting protocol — age ≥12 years
· IV/IM
15 mg/kg IV q6h
Atovaquone PO/enteral + azithromycin IV — severe babesiosis (hospitalized)
· IV/IM
Atovaquone 20 mg/kg q12h + azithromycin 10 mg/kg IV q24h
Ceftriaxone + vancomycin IV — orbital cellulitis
· IV/IM
Ceftriaxone 50 mg/kg q12h + vancomycin per starting protocol (17.5 mg/kg q6h <12 y)
Clindamycin IV + levofloxacin IV — orbital cellulitis, severe beta-lactam allergy
· IV/IM
Clindamycin 13 mg/kg q8h + levofloxacin 10 mg/kg q12h (<5 y) or q24h (≥5 y)
Gentamicin IM + azithromycin PO — gonorrhea, severe cephalosporin allergy
· Adolescent
FIXED: Gentamicin 240 mg IM once + azithromycin 2 g PO once
Clindamycin IV + gentamicin IV — PID inpatient, beta-lactam allergy
· Adolescent
FIXED: Clindamycin 900 mg IV q8h + gentamicin 3–5 mg/kg IV q24h